rmcassleman

Our analysis of earlier earnings waves highlighted a clear trend: companies actively shedding non-core assets to regain focus. The mid-February earnings window (Feb 14–22) demonstrated the tangible financial outcomes of that strategy. We are seeing a distinct shift in market expectations, characterized by significant M&A activity, a strict demand for GAAP profitability among mid-caps, and a low tolerance for administrative missteps. For the C-Suite, the mandate for 2026 is straightforward....

The latest wave of MedTech earnings (Zimmer Biomet, Baxter, Teleflex, Dexcom, West Pharma) delivered a brutal but clarifying message to the industry: Complexity is now a liability. For the last decade, the winning strategy was "bigger is safer." Accumulate assets, bundle contracts, and ride the scale. In 2026, that logic has inverted. The market is aggressively punishing broad portfolios and rewarding ruthless specialization. Here are the three signals from this week that every executive...

Selected earnings coverage of Medical Device companies from 2-2-2025 through 2-7-2026 indicate that execution is still the most critical part of successful company culture. Boston Scientific, GE Healthcare, Siemens Healthineers, and Steris all show this focus will be around in 2026 and beyond.